STADA ARZNEIMITTEL AG

History

Year	Detail
1895	The company was founded in Germany in 1895. It focused on producing and distributing generic medicines. Over the years, it expanded its portfolio to include prescription and over-the-counter products.
1938	The company opened a branch in Munich, which was hit by the 1944 bombing attacks. STADA's offices were then moved to Halle an der Saale. At the end of the war, STADA's work came to a halt, as Halle was located in the Soviet-occupied zone.
1948	Stada was founded in 1948 in two separate cooperatives in the territory of the former Federal Republic of Germany. In northern Germany, it is now STADA North, headquartered in Essen; in southern Germany, it is STADA South, based in Tübingen.
1954	The two cooperatives that emerged after the end of the war, STADA North and STADA South, merged in 1954 to become one company: STADA GmbH, headquartered in Frankfurt am Main.
1971	Two companies connected to STADA were founded: NIDDAPHARM GmbH and STADA-CHEMIE GmbH. STADA also purchased UZARA-Werk GmbH.
1975	The company decided to expand its product line with generics and established STADAPHARM GmbH. The first licenses were obtained.
1986	The company acquired Helvepharm AG, a Swiss-based pharmaceutical company, to expand its reach and product offerings in the European market.
1990	Stada acquired Eurogenerics SA, a key player in the generic medicines sector, to strengthen its position in the growing market for generic drugs.
1991	The company acquired Centrafarm B.V., a Dutch pharmaceutical company, to expand and strengthen its generics business portfolio.
1992	STADA began its business activities in Asia with STADA Pharmaceuticals (Asia) Ltd. in Hong Kong.
1996	The company acquired ALIUD PHARMA GmbH as a generic second line in Germany and expanded in France (EG Laboratories EuroGenerics S.A.) and the Czech Republic (ALIUD PHARMA CZ s.r.o.).
2000	The company purchased Clonmel Healthcare Ltd., the market leader in the Irish generics market.
2001	Stada expanded its Asian business with two acquisitions: The acquisition of Croma Medic Ltd. in the Philippines and Hong Kong-based Health Vision Enterprise Ltd.
2002	The company acquired the marketing and sales activities of the Italian pharmaceutical company Crinos SpA, Milan.
2004	The company acquired Nizhpharm, a pharmaceutical company based in Russia, to expand its regional presence.
2007	The company acquired the Russian MAKIZ Group, one of the fastest-growing suppliers in the Russian pharmaceutical market.
2011	Stada collaborated with Gedeon Richter Plc. to develop two biosimilar products for the monoclonal antibodies Rituximab and Trastuzumab.
2012	The company acquired Spirig Pharma AG, Egerkingen, a Swiss pharmaceutical company.
2018	The company acquired the Nizoral brand from Johnson & Johnson, which included the rights to the Nizoral product line. Nizoral is well known for its medicated shampoos and treatments for dandruff and seborrheic dermatitis.
2019	Stada acquired a branded OTC portfolio from GSK to strengthen the skin care business in Europe.
2019	The company acquired Walmark, a leading consumer healthcare company in Central Europe, by investing in a $660 million OTC portfolio from Takeda in Russia.
2020	Stada partnered with Alvotech, a biopharmaceutical company specializing in biosimilars. The partnership aimed to bring multiple high-quality biosimilar products to European markets and selected terrorists.
2021	Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe.
2022	Stada strengthened its Specialty business by launching Kinpeygo, an orphan drug for adults with primary IgA nephropathy.
2023	Xbrane, in partnership with the company, launched Ranibizumab biosimilar to support patient access in Europe. The product marked Xbrane’s first commercial launch and Stada’s first co-development asset in its growing biosimilar portfolio.
2023	The company significantly expanded its European Consumer Healthcare portfolio by acquiring another range of well-established and leading local and regional consumer healthcare brands from Sanofi in European countries, including Belgium, Germany, Hungary, Spain, the United Kingdom, and Nordic countries.
2023	Stada partnered with CR Sanjiu to broaden the distribution and promotion of cough and cold brands such as Shidagong, Gelite, and Ruike in China.
2024	Xbrane and Stada partnered with Valorum Biologics to commercialize ranibizumab biosimilar candidates in the U.S.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.